Glucocorticoid treatment in early rheumatoid arthritis

Abstract

Glucocorticoids (GCs) have been an invaluable tool in the treatment of patients with rheumatoid arthritis (RA) for decades, with a focus mainly on symptom management. In addition, several studies in the last 15 years have shown that GCs are also disease-modifying in patients with RA - which implies that they inhibit radiographic progression. These effects seem to be especially important in the early course of disease. Nonetheless, there is still a lack of knowledge concerning optimal therapeutic strategies with GCs, particularly regarding patient selection and optimal dosage schedules.